Related Experiment Video

Updated: Aug 14, 2026

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice
06:07

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

Published on: October 6, 2022

Management of hepatitis C/HIV coinfection

Jürgen K Rockstroh1

  • 1Department of Medicine I, University of Bonn, Bonn, Germany. rockstroh@uni-bonn.de

Current Opinion in Infectious Diseases
|December 24, 2005
PubMed

Insights

Pegylated interferon plus ribavirin is a safe and effective treatment for hepatitis C virus (HCV) coinfection in individuals with HIV. This combination therapy offers sustained virological response rates over 40% for HIV/HCV patients.

Area of Science:

  • Hepatology
  • Infectious Diseases
  • Antiviral Therapy

Background:

  • Hepatitis C virus (HCV) coinfection affects one-third of HIV-infected individuals in Europe and the USA.
  • Chronic HCV infection is a leading cause of liver disease, morbidity, and mortality in HIV patients, especially with the advent of highly active antiretroviral therapy (HAART).
  • Urgent need for effective treatment strategies for HCV coinfection in HIV-positive individuals.

Purpose of the Study:

  • To review current treatment strategies for managing hepatitis C virus (HCV) coinfection in patients with human immunodeficiency virus (HIV).
  • To evaluate the efficacy and safety of available therapies for HIV/HCV coinfected patients.
  • To identify factors influencing treatment outcomes in this population.

Main Methods:

  • Review of recent clinical studies and treatment guidelines for HIV/HCV coinfection.
  • Analysis of data on pegylated interferon/ribavirin combination therapy.
  • Assessment of adverse event management and antiretroviral selection in coinfected patients.

Main Results:

  • Pegylated interferon/ribavirin combination therapy has significantly improved treatment options, achieving sustained virological response rates exceeding 40% in HIV/HCV patients.
  • Improved management of adverse events and optimized antiretroviral selection have reduced complications and enhanced overall treatment outcomes.
  • Treatment with pegylated interferon plus ribavirin demonstrates safety and efficacy in this coinfected population.

Conclusions:

  • Pegylated interferon plus ribavirin is a safe and effective treatment for HIV/HCV coinfected patients.
  • A treatment duration of 48 weeks is recommended for HCV genotypes 2 or 3.
  • HCV genotype 2 or 3 and early treatment response are positive predictors of sustained virological response.
Abstract

More Related Videos

A Protocol for Analyzing Hepatitis C Virus Replication13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...